Drug Approval | May 14, 2026
Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
We are building an AI-native operating system for pharma sales and distribution
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The clinical study in France evaluated the safety and feasibility of Robocath’s robotic-assisted coronary intervention platform across complex cardiac cases.
Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The event will bring together industrial leaders, technology providers, and policymakers to discuss real-world Industrial AI applications in Bangalore
Subscribe To Our Newsletter & Stay Updated
